Health Care [ 4/12 ] | Health Care Equipment & Supplies [ 31/74 ]
NYSE | Common Stock
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally.
The company offers peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.
It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, and aspiration pump under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as detachable coils to treat patients with a wide range of neurovascular lesions under the Penumbra SMART COIL and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands.
In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products.
Further, it offers neurosurgical tools comprising Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum.
The company sells its products through direct sales organizations and distributors.
Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 20, 25 | 0.97 Increased by +27.63% | 0.89 Increased by +8.54% |
| Oct 30, 24 | 0.85 Increased by +26.87% | 0.69 Increased by +23.19% |
| Jul 30, 24 | 0.64 Increased by +48.84% | 0.56 Increased by +14.29% |
| May 7, 24 | 0.41 Increased by +78.26% | 0.38 Increased by +7.89% |
| Feb 22, 24 | 0.76 Increased by +375.00% | 0.70 Increased by +8.57% |
| Nov 2, 23 | 0.67 Increased by +6.60 K% | 0.45 Increased by +48.89% |
| Aug 1, 23 | 0.43 Increased by +4.20 K% | 0.28 Increased by +53.57% |
| May 2, 23 | 0.23 Increased by +2.40 K% | 0.11 Increased by +109.09% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 315.52 M Increased by +10.83% | 33.68 M Decreased by -37.87% | Increased by +10.68% Decreased by -43.95% |
| Sep 30, 24 | 301.04 M Increased by +11.11% | 29.53 M Increased by +220.46% | Increased by +9.81% Increased by +188.42% |
| Jun 30, 24 | 299.40 M Increased by +14.49% | -60.20 M Decreased by -417.51% | Decreased by -20.11% Decreased by -377.31% |
| Mar 31, 24 | 278.65 M Increased by +15.43% | 11.00 M Increased by +28.50% | Increased by +3.95% Increased by +11.32% |
| Dec 31, 23 | 284.68 M Increased by +28.69% | 54.22 M Increased by +1.30 K% | Increased by +19.05% Increased by +986.70% |
| Sep 30, 23 | 270.95 M Increased by +26.80% | 9.21 M Increased by +505.72% | Increased by +3.40% Increased by +419.97% |
| Jun 30, 23 | 261.50 M Increased by +25.51% | 18.96 M Increased by +614.24% | Increased by +7.25% Increased by +509.71% |
| Mar 31, 23 | 241.40 M Increased by +18.39% | 8.56 M Increased by +10.74 K% | Increased by +3.55% Increased by +9.05 K% |